valproic acid has been researched along with Astrocytoma, Grade IV in 61 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 9.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| " Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile." | 8.93 | Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence. ( Ii, N; Kawamura, T; Kobayashi, S; Nomoto, Y; Ochiai, S; Sakuma, H; Takada, A; Toyomasu, Y; Watanabe, Y; Yamashita, Y, 2016) |
| "Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug is used to treat epileptic seizure of glioblastoma patients." | 7.85 | Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. ( Eckert, M; Huber, SM; Klumpp, L, 2017) |
| "We studied the potential mechanisms of valproic acid (VPA) in the treatment of glioblastoma multiforme (GBM)." | 7.85 | Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. ( Chen, CP; Chen, CY; Chen, PC; Fan, CC; Hsiao, SH; Liang, YC; Tseng, JH, 2017) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 7.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 7.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs." | 7.78 | Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. ( Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C, 2012) |
| " In this study, we have examined the ability of the histone deacetylase inhibitor, valproic acid (VPA) to modulate gene expression and sensitize glioblastoma cell lines to the cytotoxic effects of etoposide in vitro." | 7.74 | Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. ( Aguilera, D; Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE; Zhang, M, 2007) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 7.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 6.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary." | 5.51 | AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. ( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "Valproic acid (VPA) treatment protected hippocampal neurons from radiation-induced damage in both cell culture and animal models." | 5.42 | Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. ( DeWees, TA; Engelbach, JA; Garbow, JR; Hallahan, AN; Hallahan, DE; Karvas, RM; Laszlo, A; Thotala, D, 2015) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 5.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 5.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Valproic acid (VPA) is a potential anticancer agent that belongs to a class of histone deacetylase (HDAC) inhibitors, targeting the epigenetic control of gene functions in cancer cells." | 5.38 | Effect of valproic acid on the outcome of glioblastoma multiforme. ( Chen, PY; Chen, SM; Huang, YC; Lee, ST; Lu, YJ; Tsai, CN; Tsai, HC; Wei, KC, 2012) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 5.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| " Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile." | 4.93 | Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence. ( Ii, N; Kawamura, T; Kobayashi, S; Nomoto, Y; Ochiai, S; Sakuma, H; Takada, A; Toyomasu, Y; Watanabe, Y; Yamashita, Y, 2016) |
| " The impact of the chemotherapeutic temozolomide (TMZ) in combination with valproic acid (VPA) was tested in two pediatric glioblastoma-derived cell lines." | 3.96 | Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro. ( Gielen, G; Hüttelmaier, S; Klusmann, JH; Kramm, C; Kühnöl, CD; Pietsch, T; Pötschke, R, 2020) |
| "We studied the potential mechanisms of valproic acid (VPA) in the treatment of glioblastoma multiforme (GBM)." | 3.85 | Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. ( Chen, CP; Chen, CY; Chen, PC; Fan, CC; Hsiao, SH; Liang, YC; Tseng, JH, 2017) |
| "Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug is used to treat epileptic seizure of glioblastoma patients." | 3.85 | Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. ( Eckert, M; Huber, SM; Klumpp, L, 2017) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 3.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 3.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs." | 3.78 | Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. ( Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C, 2012) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 3.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " In this study, we have examined the ability of the histone deacetylase inhibitor, valproic acid (VPA) to modulate gene expression and sensitize glioblastoma cell lines to the cytotoxic effects of etoposide in vitro." | 3.74 | Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. ( Aguilera, D; Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE; Zhang, M, 2007) |
| "Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis." | 2.72 | Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma. ( Camphausen, K; Degorre, C; Mathen, P; Tofilon, P, 2021) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 2.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Glioblastoma multiforme is the most common malignant primary brain tumor in adults." | 1.72 | Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. ( Doello, K; Mesas, C; Ortiz, R; Perazzoli, G; Quiñonero, F; Rama, AR; Vélez, C, 2022) |
| "Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary." | 1.51 | AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. ( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients." | 1.43 | Prognostic relevance of epilepsy at presentation in glioblastoma patients. ( Berendsen, S; Bours, V; Broekman, ML; Kauw, F; Kroonen, J; Poulet, C; Robe, PA; Seute, T; Snijders, TJ; Spliet, WG; Varkila, M; Willems, M, 2016) |
| "Valproic acid (VPA) treatment protected hippocampal neurons from radiation-induced damage in both cell culture and animal models." | 1.42 | Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. ( DeWees, TA; Engelbach, JA; Garbow, JR; Hallahan, AN; Hallahan, DE; Karvas, RM; Laszlo, A; Thotala, D, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 1.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 1.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "Valproic acid (VPA) is a potential anticancer agent that belongs to a class of histone deacetylase (HDAC) inhibitors, targeting the epigenetic control of gene functions in cancer cells." | 1.38 | Effect of valproic acid on the outcome of glioblastoma multiforme. ( Chen, PY; Chen, SM; Huang, YC; Lee, ST; Lu, YJ; Tsai, CN; Tsai, HC; Wei, KC, 2012) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of epilepsy." | 1.36 | Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. ( Ferreri, AM; Guerra, F; Orlandi, M; Papi, A; Rocchi, P, 2010) |
| "Valproic acid (VPA) has been recently investigated for its anticancer properties in different tumors, including malignant gliomas." | 1.34 | Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (11.48) | 29.6817 |
| 2010's | 48 (78.69) | 24.3611 |
| 2020's | 6 (9.84) | 2.80 |
| Authors | Studies |
|---|---|
| Degorre, C | 1 |
| Tofilon, P | 2 |
| Camphausen, K | 3 |
| Mathen, P | 1 |
| Doello, K | 3 |
| Mesas, C | 3 |
| Quiñonero, F | 3 |
| Rama, AR | 3 |
| Vélez, C | 3 |
| Perazzoli, G | 3 |
| Ortiz, R | 3 |
| Natale, G | 1 |
| Fini, E | 1 |
| Calabrò, PF | 1 |
| Carli, M | 1 |
| Scarselli, M | 1 |
| Bocci, G | 1 |
| Krauze, AV | 2 |
| Zhao, Y | 1 |
| Li, MC | 1 |
| Shih, J | 2 |
| Jiang, W | 1 |
| Tasci, E | 1 |
| Cooley Zgela, T | 1 |
| Sproull, M | 1 |
| Mackey, M | 1 |
| Shankavaram, U | 1 |
| Valiulytė, I | 1 |
| Curkūnavičiūtė, R | 1 |
| Ribokaitė, L | 1 |
| Kazlauskas, A | 2 |
| Vaitkevičiūtė, M | 1 |
| Skauminas, K | 1 |
| Valančiūtė, A | 2 |
| Pötschke, R | 1 |
| Gielen, G | 1 |
| Pietsch, T | 1 |
| Kramm, C | 1 |
| Klusmann, JH | 1 |
| Hüttelmaier, S | 1 |
| Kühnöl, CD | 1 |
| Kresbach, C | 1 |
| Bronsema, A | 1 |
| Guerreiro, H | 1 |
| Rutkowski, S | 1 |
| Schüller, U | 1 |
| Winkler, B | 1 |
| Kavaliauskaitė, D | 1 |
| Stakišaitis, D | 1 |
| Martinkutė, J | 1 |
| Šlekienė, L | 1 |
| Balnytė, I | 1 |
| Lesauskaitė, V | 1 |
| Chang, YL | 1 |
| Huang, LC | 1 |
| Chen, YC | 1 |
| Wang, YW | 1 |
| Hueng, DY | 1 |
| Huang, SM | 1 |
| Tarasenko, N | 1 |
| Chekroun-Setti, H | 1 |
| Nudelman, A | 1 |
| Rephaeli, A | 1 |
| Eckert, M | 1 |
| Klumpp, L | 1 |
| Huber, SM | 1 |
| Garcia, CG | 1 |
| Kahn, SA | 1 |
| Geraldo, LHM | 1 |
| Romano, I | 1 |
| Domith, I | 1 |
| Silva, DCLE | 1 |
| Dos Santos Assunção, F | 1 |
| Ferreira, MJ | 1 |
| Portugal, CC | 1 |
| de Souza, JM | 1 |
| Romão, LF | 1 |
| Netto, ADP | 1 |
| Lima, FRS | 1 |
| Cossenza, M | 1 |
| Ishiguro, Y | 1 |
| Kobayashi, M | 1 |
| Ideno, M | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Iseki, K | 1 |
| Lu, VM | 1 |
| Texakalidis, P | 1 |
| McDonald, KL | 1 |
| Mekary, RA | 1 |
| Smith, TR | 1 |
| Sachkova, A | 1 |
| Sperling, S | 1 |
| Mielke, D | 1 |
| Schatlo, B | 1 |
| Rohde, V | 1 |
| Ninkovic, M | 1 |
| Lange, F | 1 |
| Weßlau, K | 1 |
| Porath, K | 1 |
| Hörnschemeyer, J | 1 |
| Bergner, C | 1 |
| Krause, BJ | 1 |
| Mullins, CS | 1 |
| Linnebacher, M | 1 |
| Köhling, R | 1 |
| Kirschstein, T | 1 |
| Luo, D | 1 |
| Fraga-Lauhirat, M | 1 |
| Millings, J | 1 |
| Ho, C | 1 |
| Villarreal, EM | 1 |
| Fletchinger, TC | 1 |
| Bonfiglio, JV | 1 |
| Mata, L | 1 |
| Nemesure, MD | 1 |
| Bartels, LE | 1 |
| Wang, R | 1 |
| Rigas, B | 1 |
| Mackenzie, GG | 1 |
| Chen, JC | 1 |
| Lee, IN | 1 |
| Huang, C | 1 |
| Wu, YP | 1 |
| Chung, CY | 1 |
| Lee, MH | 1 |
| Lin, MH | 1 |
| Yang, JT | 1 |
| Guthrie, G | 1 |
| Eljamel, S | 2 |
| Barker, CA | 1 |
| Bishop, AJ | 1 |
| Chang, M | 1 |
| Beal, K | 1 |
| Chan, TA | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 1 |
| Walchenbach, R | 1 |
| Taphoorn, MJ | 1 |
| Vecht, CJ | 2 |
| Weller, M | 3 |
| Booth, L | 1 |
| Roberts, JL | 1 |
| Conley, A | 1 |
| Cruickshanks, N | 1 |
| Ridder, T | 1 |
| Grant, S | 1 |
| Poklepovic, A | 1 |
| Dent, P | 1 |
| Rubner, Y | 1 |
| Muth, C | 1 |
| Strnad, A | 1 |
| Derer, A | 1 |
| Sieber, R | 1 |
| Buslei, R | 1 |
| Frey, B | 1 |
| Fietkau, R | 1 |
| Gaipl, US | 1 |
| Bezecny, P | 1 |
| Alvarez, AA | 1 |
| Field, M | 1 |
| Bushnev, S | 1 |
| Longo, MS | 1 |
| Sugaya, K | 1 |
| Yuan, Y | 1 |
| Xiang, W | 1 |
| Qing, M | 1 |
| Yanhui, L | 1 |
| Jiewen, L | 1 |
| Yunhe, M | 1 |
| Tinchon, A | 1 |
| Oberndorfer, S | 1 |
| Marosi, C | 1 |
| Gleiss, A | 1 |
| Geroldinger, A | 1 |
| Sax, C | 1 |
| Sherif, C | 1 |
| Moser, W | 1 |
| Grisold, W | 1 |
| Hosein, AN | 1 |
| Lim, YC | 1 |
| Day, B | 1 |
| Stringer, B | 1 |
| Rose, S | 1 |
| Head, R | 2 |
| Cosgrove, L | 2 |
| Sminia, P | 2 |
| Fay, M | 1 |
| Martin, JH | 2 |
| Mellai, M | 1 |
| Cattaneo, M | 1 |
| Storaci, AM | 1 |
| Annovazzi, L | 1 |
| Cassoni, P | 1 |
| Melcarne, A | 1 |
| De Blasio, P | 1 |
| Schiffer, D | 1 |
| Biunno, I | 1 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Smith, S | 1 |
| Tofilon, PJ | 1 |
| Fine, HA | 1 |
| Thotala, D | 1 |
| Karvas, RM | 1 |
| Engelbach, JA | 1 |
| Garbow, JR | 1 |
| Hallahan, AN | 1 |
| DeWees, TA | 1 |
| Laszlo, A | 1 |
| Hallahan, DE | 1 |
| Berendsen, S | 2 |
| Varkila, M | 1 |
| Kroonen, J | 1 |
| Seute, T | 2 |
| Snijders, TJ | 1 |
| Kauw, F | 1 |
| Spliet, WG | 1 |
| Willems, M | 1 |
| Poulet, C | 1 |
| Broekman, ML | 1 |
| Bours, V | 1 |
| Robe, PA | 1 |
| Lawrence, JE | 1 |
| Steele, CJ | 1 |
| Rovin, RA | 1 |
| Belton, RJ | 1 |
| Winn, RJ | 1 |
| Happold, C | 1 |
| Gorlia, T | 2 |
| Chinot, O | 1 |
| Gilbert, MR | 1 |
| Nabors, LB | 1 |
| Wick, W | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Roth, P | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Stupp, R | 3 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Dietrich, J | 1 |
| Nahed, BV | 1 |
| Ochiai, S | 1 |
| Nomoto, Y | 1 |
| Yamashita, Y | 1 |
| Watanabe, Y | 1 |
| Toyomasu, Y | 1 |
| Kawamura, T | 1 |
| Takada, A | 1 |
| Ii, N | 1 |
| Kobayashi, S | 1 |
| Sakuma, H | 1 |
| Proske, J | 1 |
| Walter, L | 1 |
| Bumes, E | 1 |
| Hutterer, M | 1 |
| Vollmann-Zwerenz, A | 1 |
| Eyüpoglu, IY | 1 |
| Savaskan, NE | 1 |
| Seliger, C | 1 |
| Hau, P | 2 |
| Uhl, M | 1 |
| Rudà, R | 1 |
| Pellerino, A | 1 |
| Soffietti, R | 1 |
| Riva, G | 1 |
| Butta, V | 1 |
| Cilibrasi, C | 1 |
| Baronchelli, S | 1 |
| Redaelli, S | 1 |
| Dalprà, L | 1 |
| Lavitrano, M | 1 |
| Bentivegna, A | 1 |
| Fay, MF | 1 |
| Dowson, N | 1 |
| Rose, SE | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Proescholdt, M | 1 |
| Herold-Mende, C | 1 |
| Riemenschneider, MJ | 1 |
| Tseng, JH | 1 |
| Chen, CY | 1 |
| Chen, PC | 1 |
| Hsiao, SH | 1 |
| Fan, CC | 1 |
| Liang, YC | 1 |
| Chen, CP | 1 |
| Neyns, B | 1 |
| Hoorens, A | 1 |
| Papi, A | 1 |
| Ferreri, AM | 1 |
| Rocchi, P | 1 |
| Guerra, F | 1 |
| Orlandi, M | 1 |
| Rokes, CA | 1 |
| Remke, M | 1 |
| Guha-Thakurta, N | 1 |
| Witt, O | 2 |
| Korshunov, A | 1 |
| Pfister, S | 1 |
| Wolff, JE | 2 |
| Golan, M | 1 |
| Schreiber, G | 1 |
| Avissar, S | 1 |
| Roy Choudhury, S | 1 |
| Karmakar, S | 1 |
| Banik, NL | 1 |
| Ray, SK | 1 |
| Wen, PY | 1 |
| Schiff, D | 1 |
| Cairncross, JG | 1 |
| van den Bent, MJ | 1 |
| Mason, W | 1 |
| Belanger, K | 1 |
| Brandes, AA | 1 |
| Bogdahn, U | 1 |
| Macdonald, DR | 1 |
| Forsyth, P | 1 |
| Rossetti, AO | 1 |
| Lacombe, D | 1 |
| Mirimanoff, RO | 1 |
| Tsai, HC | 1 |
| Wei, KC | 1 |
| Tsai, CN | 1 |
| Huang, YC | 1 |
| Chen, PY | 1 |
| Chen, SM | 1 |
| Lu, YJ | 1 |
| Lee, ST | 1 |
| Alvarez-Breckenridge, CA | 1 |
| Yu, J | 1 |
| Price, R | 1 |
| Wei, M | 1 |
| Wang, Y | 1 |
| Nowicki, MO | 1 |
| Ha, YP | 1 |
| Bergin, S | 1 |
| Hwang, C | 1 |
| Fernandez, SA | 1 |
| Kaur, B | 1 |
| Caligiuri, MA | 1 |
| Chiocca, EA | 1 |
| Broekman, M | 1 |
| Snijders, T | 1 |
| van Es, C | 1 |
| de Vos, F | 1 |
| Regli, L | 1 |
| Robe, P | 1 |
| Asklund, T | 1 |
| Kvarnbrink, S | 1 |
| Holmlund, C | 1 |
| Wibom, C | 1 |
| Bergenheim, T | 1 |
| Henriksson, R | 1 |
| Hedman, H | 1 |
| Guthrie, GD | 1 |
| Schweigerer, L | 1 |
| Driever, PH | 1 |
| Wolff, J | 1 |
| Pekrun, A | 1 |
| Grewal, J | 1 |
| Dellinger, CA | 1 |
| Yung, WK | 1 |
| Das, CM | 1 |
| Aguilera, D | 1 |
| Vasquez, H | 1 |
| Prasad, P | 1 |
| Zhang, M | 1 |
| Gopalakrishnan, V | 1 |
| Ciusani, E | 1 |
| Balzarotti, M | 1 |
| Calatozzolo, C | 1 |
| de Grazia, U | 1 |
| Boiardi, A | 1 |
| Salmaggi, A | 1 |
| Croci, D | 1 |
| Morikawa, N | 2 |
| Mori, T | 2 |
| Kawashima, H | 2 |
| Takeyama, M | 2 |
| Hori, S | 2 |
| Abe, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for valproic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials as Topic; Exportin 1 Protein; Glioblastoma; Humans; Karyopherins; N | 2021 |
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?
Topics: Antimanic Agents; Bipolar Disorder; Brain Neoplasms; Glioblastoma; Humans; Lithium; Lithium Carbonat | 2023 |
The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis.
Topics: Anticonvulsants; Brain Neoplasms; Cohort Studies; Glioblastoma; Humans; Retrospective Studies; Survi | 2018 |
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Depsipeptides; Epigenesis, Genetic; Glioblastoma | 2014 |
Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Analysis; Treatme | 2014 |
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Topics: Anticonvulsants; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation-Sensitizing Age | 2016 |
Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2012 |
Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Neoplasms; Carbamazepine; Cohort Studies; Female; Gl | 2013 |
2 trials available for valproic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
51 other studies available for valproic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Topics: Antineoplastic Agents, Alkylating; Glioblastoma; Hedgehog Proteins; Histone Deacetylase Inhibitors; | 2023 |
The Anti-Tumorigenic Activity of Sema3C in the Chick Embryo Chorioallantoic Membrane Model.
Topics: Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Glioblastoma; Humans; Neoplasm In | 2019 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.
Topics: Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Enhancer of Zeste Homolog 2 Prote | 2017 |
The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyc | 2017 |
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2018 |
Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma.
Topics: Action Potentials; Anticonvulsants; Brain Neoplasms; Calcium; Calcium-Calmodulin-Dependent Protein K | 2017 |
Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Topics: Amino Acid Transport System y+; Animals; Ascorbic Acid; Brain Neoplasms; Cell Death; Cell Line, Tumo | 2018 |
Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP-Binding Cassette Transporters; Brain Neoplasms; C | 2018 |
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Pr | 2019 |
Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gliob | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
Does the choice of antiepileptic drug have an impact on the survival of glioblastoma multiforme?
Topics: Antineoplastic Agents; Brain Neoplasms; Enzyme Inhibitors; Female; Glioblastoma; Humans; Male; Valpr | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Fem | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone | 2015 |
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Cells; Brain Neoplasms; Chemoradiotherapy; Fem | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cranial Irradiation; | 2015 |
Prognostic relevance of epilepsy at presentation in glioblastoma patients.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Glioblastoma; Humans; Immunohistochemistr | 2016 |
Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.
Topics: Aminolevulinic Acid; Anti-Inflammatory Agents; Anticonvulsants; Desipramine; Dexamethasone; Drug The | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Shape; Cell Survival; Cell Transformation, | 2016 |
Valproate in Adjuvant Glioblastoma Treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Topics: Animals; Aryldialkylphosphatase; Bcl-2-Like Protein 11; Blotting, Western; Brain Neoplasms; Cell Lin | 2017 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2010 |
Sorafenib plus valproic acid for infant spinal glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extrac | 2010 |
Antidepressants elevate GDNF expression and release from C₆ glioma cells in a β-arrestin1-dependent, CREB interactive pathway.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents | 2011 |
Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells.
Topics: Albumin-Bound Paclitaxel; Albumins; Apoptosis; Apoptosis Inducing Factor; ATP Binding Cassette Trans | 2011 |
Valproic acid as the AED of choice for patients with glioblastoma? The jury is out.
Topics: Anticonvulsants; Brain Neoplasms; Glioblastoma; Humans; Seizures; Valproic Acid | 2011 |
Effect of valproic acid on the outcome of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; | 2012 |
The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
Topics: Animals; Cell Line; Cytotoxicity, Immunologic; Glioblastoma; Histone Deacetylase Inhibitors; Humans; | 2012 |
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasm | 2012 |
Valproic acid treatment of glioblastoma multiforme in a child.
Topics: Child; Enzyme Inhibitors; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Male; Valproic Acid | 2004 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cel | 2007 |
Change of valproic acid concentrations during cerebrospinal fluid perfusion chemotherapy.
Topics: Adult; Anticonvulsants; Central Nervous System Neoplasms; Chemotherapy, Cancer, Regional Perfusion; | 2000 |
Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2000 |